非霍奇金淋巴瘤诊断市场研究报告按诊断技术（免疫组织化学、流式细胞术、基因检测、细胞遗传学分析、分子诊断）、按产品类型（试剂、仪器、软件、试剂盒）、按最终用户（医院、诊断实验室、研究机构、制药公司）、按疾病类型（弥漫性大 B 细胞淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤、伯基特淋巴瘤）和按地区（北美、欧洲、南美、亚太地区、中东和非洲）- 到 2034 年的预测
ID: MRFR/HC/32186-HCR | 100 Pages | Author: Rahul Gotadki| August 2025
全球非霍奇金淋巴瘤诊断市场概览根据 MRFR 分析，2022 年非霍奇金淋巴瘤诊断市场规模预计为 4.08（十亿美元）。非霍奇金淋巴瘤诊断市场预计将从 2023 年的 4.29（十亿美元）增长到 2032 年的 6.8（十亿美元）。非霍奇金淋巴瘤诊断市场 CAGR（增长率）预计约为 5.24%在预测期内（2024 - 2032）。
| Report Attribute/Metric | Details |
| Market Size 2024 | 4.76 (USD Billion) |
| Market Size 2025 | 5.01 (USD Billion) |
| Market Size 2034 | 7.93 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 5.24 % (2025 - 2034) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2034 |
| Historical Data | 2020 - 2024 |
| Market Forecast Units | USD billion |
| Key Companies Profiled | Siemens Healthineers, AstraZeneca, Quotient Limited, AbbVie, Celgene, Abbott Laboratories, Bristol-Myers Squibb, Takeda Pharmaceutical, Gilead Sciences, Thermo Fisher Scientific, Eli Lilly, Merck, Roche, Novartis, Amgen |
| Segments Covered | Diagnostic Technique, Product Type, End User, Disease Type, Regional |
| Key Market Opportunities | Advanced biomarker development, AI-driven diagnostic tools, Rising prevalence of lymphoma, Increased funding for research, Expansion in emerging markets |
| Key Market Dynamics | Aging population increasing incidence, Advancements in diagnostic technology, Rising awareness and screening programs, Expansion of healthcare infrastructure, High prevalence of risk factors |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
In 2024, the Non-Hodgkin Lymphoma Diagnostic Market was valued at 4.76 USD billion.
By 2034, the market is expected to grow to 7.93 USD billion.
The market is anticipated to have a CAGR of 5.24% during the forecast period from 2024 to 2032.
North America is the dominant region, with a market value of 2.21 USD billion in 2023 and projected to be 3.43 USD billion by 2032.
Immunohistochemistry is valued at 1.0 USD billion in 2023 and 1.6 USD billion in 2032, while Flow Cytometry is projected to grow from 0.8 USD billion to 1.2 USD billion in the same timeframe.
Key players include Siemens Healthineers, AstraZeneca, Quotient Limited, and AbbVie, among others.
Europe's market is expected to grow from 1.02 USD billion in 2023 to 1.52 USD billion by 2032.
The APAC region is valued at 0.75 USD billion in 2023 and is projected to increase to 1.15 USD billion by 2032.
Emerging technologies and increasing awareness of diagnostic procedures present opportunities, while high costs and regulatory hurdles are notable challenges.
Molecular Diagnostics is projected to grow from 0.59 USD billion in 2023 to 1.2 USD billion by 2032.
Comments
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
